Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

Taku Fujimura, Kayo Tanita, Yota Sato, Yumi Kambayashi, Sadanori Furudate, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

研究成果: Article査読

3 被引用数 (Scopus)

抄録

Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

本文言語English
ページ(範囲)29-32
ページ数4
ジャーナルCase Reports in Oncology
11
1
DOI
出版ステータスPublished - 2018 1月 19

ASJC Scopus subject areas

  • 腫瘍学

フィンガープリント

「Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル